Belite Bio (BLTE) to offer ADS and warrants
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares and Warrants
May 30, 2023 4:01 PM EDTSAN DIEGO, May 30, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (Belite Bio or the Company), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have significant unmet medical needs, today announced that it has commenced an underwritten public offering of American Depositary Shares (ADSs), each representing one of its ordinary shares, and warrants to purchase ordinary shares represented by ADSs. All of the securities in the offering are to be sold by Belite Bio. The offering is subject to market... More
